fig4
![Changes in hepatic fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients: a prospective observational study](https://image.oaes.cc/a64dc854-654e-4a24-a157-282bdd2262b0/5000.fig.4.jpg)
Figure 4. Cumulative hazard of HCC in patients with HCV after the end of DAA therapy, shown by Cox regression model according to fibrotic changes after DAA. Cum: Cumulative; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; DAA: direct acting antiviral.